-
-
-
-
-
-
-
What is Safeguard’s typical transaction size?
To help a partner company realize its potential, we provide $5 million to $50 million in capital, along with significant strategic, operational and executive management resources. Our transactions typically fall within the following guidelines:
- $25 million - $50 million — Growth Buyout Financing
- $10 million - $25 million — Growth Equity Financing
- $ 5 million - $10 million — Early-Stage Financing
What is Safeguard’s market focus?
We prefer to partner with technology and life sciences partner companies in large or growing markets throughout the United States and Canada that possess competitive advantages, such as proprietary technology, intellectual property or other differentiators, that act as barriers to entry for other companies.
What is Safeguard’s typical ownership position?
We seek either primary or minority ownership positions through expansion capital, management buyouts, recapitalizations, early-stage financings or other transaction structures.
What does Safeguard typically look for in potential technology partner companies?
Safeguard partners with growth-stage, entrepreneurial technology companies that have a competitive advantage in the above markets. We look for strong management teams in companies that provide the necessary solutions for those sectors, including analytics/business intelligence, enterprise applications and infrastructure/security/communication. We are particularly interested in technology companies that focus on:
- Software as a Service (SaaS)
- Technology Enabled Services
- Internet-based Businesses
What does Safeguard typically look for in potential life sciences partner companies?
Safeguard partners with growth-stage, entrepreneurial life sciences companies who have a competitive advantage in markets that represent sizeable opportunities. We look for strong management teams in companies that address key themes throughout our target markets. We are particularly interested in life sciences companies that focus on:
- Molecular Diagnostics
- Medical Devices
- Specialty Pharmaceuticals
What’s the difference between Safeguard’s business model and that of venture capital or private equity firms?
Safeguard’s business model affords us the ability to be patient in guiding the partner company’s growth, while continually building value for our shareholders.
Safeguard doesn’t play as early as venture capital, and doesn’t play as late as the private equity community. From the entrepreneur’s vantage point, we’re not forced into a premature exit to return capital to limited partners, so we can raise a new fund every three years. There is no cut-off date to sell our ownership position. Generally, we hold a partner company stage as long as we believe the risk-adjusted value of that stake is minimized by our ownership and effort.
Beyond providing capital, how else does Safeguard add value to its technology and life sciences partner companies?
Through our team of dedicated and experienced professionals, we offer an extensive range of strategic, operational and management services, including:
- Growth capital
- Strategic planning
- Acquisition support
- Management support
- Business development
- Legal and finance/accounting support